{"disease":{"id":"oesophageal-disease","name":"oesophageal disease"},"drugs":{"marketed":[{"drug_id":"omeprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"dexlansoprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexilant","generic_name":"DEXLANSOPRAZOLE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase","drug_class":"Proton Pump Inhibitor [EPC]","quality_score":67,"revenue":"300","mechanism":"Dexlansoprazole inhibits gastric acid secretion by blocking the (H+, K+)-ATPase enzyme, known as the proton pump, in gastric parietal cells."},{"drug_id":"sodium-citrate","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bss","generic_name":"SODIUM CITRATE","company_name":"B Braun","drug_phase":"marketed","molecular_target":"Calcium","drug_class":"sodium citrate","quality_score":51,"revenue":null,"mechanism":"ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A prevents blood clotting by binding free calcium, a crucial co-factor in the clotting cascade."},{"drug_id":"magnesium-silicate","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gaviscon","generic_name":"MAGNESIUM SILICATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium silicate","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"magnesium-carbonate","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"MAGNESIUM CARBONATE","company_name":"United Guardian","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"magnesium-hydroxide","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Milk of Magnesia","generic_name":"magnesium hydroxide","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Gastric acid (direct neutralization) + osmotic effect in intestine","drug_class":"Osmotic laxative, Antacid","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"metoclopramide","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reglan","generic_name":"METOCLOPRAMIDE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Dopamine-2 Receptor Antagonist","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"metoclopramide-hydrochloride","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reglan","generic_name":"Metoclopramide Hydrochloride","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Acetylcholine receptor sensitization; dopamine antagonism (implied)","drug_class":"Prokinetic agent","quality_score":10,"revenue":null,"mechanism":"Metoclopramide stimulates upper GI tract motility by sensitizing tissues to acetylcholine action."},{"drug_id":"ilaprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noltec","generic_name":"ILAPRAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitors","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"ranitidine","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zantac","generic_name":"ranitidine","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","drug_class":"H2 receptor antagonist","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"dexlan","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dexlan","company_name":"Chang Gung Memorial Hospital","drug_phase":"phase_1","molecular_target":"Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase","drug_class":"","quality_score":7,"revenue":null,"mechanism":""},{"drug_id":"famotidine","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepcid","generic_name":"famotidine","company_name":"Generic (originally Yamanouchi/Merck)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion."},{"drug_id":"dexilant","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dexilant","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"algeldrate","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gaviscon","generic_name":"ALGELDRATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"algeldrate","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"palazestrant","indication_name":"Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palazestrant","generic_name":"palazestrant","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor antagonist and degrader","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"prevacid","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"esomeprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexium","generic_name":"esomeprazole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton pump inhibitor (PPI)","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pantoprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protonix","generic_name":"pantoprazole","company_name":"Generic (originally Byk Gulden/Altana/Nycomed)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"Proton pump inhibitor (PPI)","quality_score":58,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion."},{"drug_id":"aluminum-carbonate","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"aluminum carbonate","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"aluminum carbonate","quality_score":null,"revenue":null,"mechanism":"Aluminum carbonate works by neutralizing stomach acid and forming a protective barrier over the stomach lining."},{"drug_id":"carbaldrate","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"carbaldrate","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"carbaldrate","quality_score":null,"revenue":null,"mechanism":"Carbaldrate works by reducing stomach acid production."},{"drug_id":"almasilate","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gelusil","generic_name":"ALMASILATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"almasilate","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"alum","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Alum","generic_name":"Alum","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"protonix-iv","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pantoprazole Sodium","generic_name":"Pantoprazole Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase enzyme","drug_class":"Proton pump inhibitor (PPI)","quality_score":69,"revenue":null,"mechanism":"Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells."},{"drug_id":"aciphex","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciphex","company_name":"University of Utah","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"rabeprazole-40-mg","indication_name":"Gastroesophageal Reflux Disease (GERD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole-40-mg","indication_name":"Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cimetidine","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagamet","generic_name":"CIMETIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aciphex","generic_name":"rabeprazole","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitor","quality_score":80,"revenue":null,"mechanism":"Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"cisapride","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alimix","generic_name":"CISAPRIDE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"High Risk QT Prolonging Agents","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"nizatidine","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axid Ar","generic_name":"NIZATIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"rabeprazol","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rabeprazol","company_name":"Janssen-Cilag, S.A.","drug_phase":"discontinued","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"omeprazol","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pantoprazol","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pantoprazol","company_name":"Northern Orthopaedic Division, Denmark","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexrabeprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"lansoprazole","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."},{"drug_id":"metaclopramide","indication_name":"Gastroesophageal reflux disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metaclopramide","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"discontinued","molecular_target":"Aldehyde oxidase, Myeloperoxidase, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":36,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06974903","title":"Retrospective Observational Study on GERD Management in General Hospitals in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":13750,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT05614752","title":"Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab","phase":"","overall_status":"COMPLETED","enrollment_count":10067,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05886933","title":"Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet","phase":"","overall_status":"COMPLETED","enrollment_count":9846,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT07115706","title":"JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7150,"lead_sponsor_name":"Jeil Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03666767","title":"Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries","phase":"","overall_status":"COMPLETED","enrollment_count":3850,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT05660122","title":"A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab","phase":"","overall_status":"COMPLETED","enrollment_count":2852,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05870163","title":"Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Implantica CE Reflux Ltd.","has_results":false},{"nct_id":"NCT06585176","title":"Epidemiological Studies and Risk Factor Analysis of GERD in Xiamen City","phase":"","overall_status":"COMPLETED","enrollment_count":1625,"lead_sponsor_name":"Zhongshan Hospital (Xiamen), Fudan University","has_results":false},{"nct_id":"NCT03616119","title":"Gastroesophageal Reflux Disease in Azerbaijan","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Sevda Aghayeva","has_results":false},{"nct_id":"NCT06504134","title":"Gastroesophageal Reflux Disease Diagnostic Trial","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04408105","title":"Survey Study on Barrett's Esophagus Screening","phase":"","overall_status":"COMPLETED","enrollment_count":725,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06381583","title":"A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":658,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03561883","title":"Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04306380","title":"Transoral Incisionless Fundoplication Database Repository (TIF)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT07004439","title":"A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Implantica CE Reflux Ltd.","has_results":false},{"nct_id":"NCT03561090","title":"A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":495,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02954848","title":"Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":484,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT01472939","title":"Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07125521","title":"Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare","phase":"NA","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Institute of Gastroenterology and Hepatology, Vietnam","has_results":false},{"nct_id":"NCT07127276","title":"Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of Smartphone Application GERDCare","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":380,"lead_sponsor_name":"Institute of Gastroenterology and Hepatology, Vietnam","has_results":false},{"nct_id":"NCT05701540","title":"A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":338,"lead_sponsor_name":"HK inno.N Corporation","has_results":false},{"nct_id":"NCT07160790","title":"Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":321,"lead_sponsor_name":"Onconic Therapeutics Inc.","has_results":false},{"nct_id":"NCT03848494","title":"True Short Esophagus in Gastroesophageal Reflux Disease","phase":"","overall_status":"COMPLETED","enrollment_count":311,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT06481787","title":"Zuojin Wan Combined With Woonosan Fumarate for the Treatment of GRD Combined With Depression","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT02351960","title":"Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02789800","title":"Patient-Centred Innovations for Persons With Multimorbidity - Quebec","phase":"NA","overall_status":"COMPLETED","enrollment_count":284,"lead_sponsor_name":"Université de Sherbrooke","has_results":false},{"nct_id":"NCT02637557","title":"A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":282,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06577376","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":252,"lead_sponsor_name":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","has_results":false},{"nct_id":"NCT00838526","title":"Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT02873689","title":"Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04080726","title":"Efficacy and Safety of HIP1601 Capsule","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT03184324","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":211,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT06973070","title":"Upper GI MM vs Manometry","phase":"","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Lexington Health Incorporated","has_results":false},{"nct_id":"NCT07108751","title":"Association Between Gastroesophageal Reflux Disease (GERD) Severity and Dental Caries","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT01940185","title":"A Post-Approval Study of the LINX® Reflux Management System","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Torax Medical Incorporated","has_results":false},{"nct_id":"NCT07004400","title":"A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Implantica CE Reflux Ltd.","has_results":false},{"nct_id":"NCT01696734","title":"Domperidone in Treating Patients With Gastrointestinal Disorders","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06138223","title":"The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)","phase":"NA","overall_status":"RECRUITING","enrollment_count":196,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT05365087","title":"Transoral Fundoplication Prior to Sleeve Gastrectomy Versus RNY Gastric Bypass on GERD Symptoms in Bariatric Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Lexington Health Incorporated","has_results":false},{"nct_id":"NCT02742597","title":"Patient-Centred Innovations for Persons With Multimorbidity - Ontario","phase":"NA","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03128736","title":"Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","has_results":false},{"nct_id":"NCT07344935","title":"Evaluation of the Effectiveness of the Ezisurg Stapling (Ezi Endo Lite) During Laparoscopic Nissen Sleeve Gastrectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Ezisurg Medical Co. Ltd.","has_results":false},{"nct_id":"NCT06945237","title":"Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04255693","title":"Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology","has_results":false},{"nct_id":"NCT05422404","title":"Anti-Reflux Mucosal Ablation(ARMA) and Anti-Reflux Mucosectomy(ARMS) in Gastroesophageal Reflux Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT03223116","title":"Radiofrequency Energy Delivery for Gastroesophageal Reflux Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT02384551","title":"Dietary Carbohydrate and GERD in Veterans","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT04252144","title":"Study of Dietary Patterns and Food Diversity in Russian GERD Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Russian Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07022912","title":"PPI Refractory - GERD Mechanisms in Systemic Sclerosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":147,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT07326904","title":"Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Indonesia University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}